Predicting treatment needs for moderate to severe thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thyroid eye disease (TAO) at this hospital after August 31, 2024.
- Your TAO is considered moderate to severe by standard medical criteria.
- In your more affected eye, the clinical activity score (CAS) is 3 or higher on a 7-point scale.
- You have not received a high cumulative dose of steroids (equivalent to more than 1 gram of methylprednisolone) for your eye condition.
- You do not have a sight-threatening complication needing urgent treatment.
- You are not pregnant or breastfeeding, and you are healthy enough for an orbital MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to build a better system for diagnosing and treating thyroid-associated ophthalmopathy (a thyroid eye condition). It may help improve care for people with this disease, and also involves healthy volunteers as a comparison group.
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
This trial tests whether orbital (eye-socket) radiotherapy can improve active Graves’ orbitopathy, a condition that affects the eyes and eye muscles. It may help reduce eye inflammation and related symptoms if you meet the specific activity and severity criteria.
This study looks at how doxycycline (an antibiotic) affects thyroid eye disease using special imaging pictures. It may help doctors better understand disease activity and how well treatments work.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
This study uses MRI scans of the eye area to better understand and classify thyroid eye disease (TED). It aims to help doctors predict outcomes and personalize treatment. You may be eligible if you have stable TED or are a healthy volunteer.
Hear when a new Thyroid Associated Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.